Thomas Chun Wai Chan1, Chandra Bala2, Anna Siu3, Fiona Wan3, Andrew White4. 1. University of Sydney, Sydney, Australia. 2. Macquarie University, Sydney, Australia; Personal Eyes, Sydney, Australia. 3. Personal Eyes, Sydney, Australia. 4. University of Sydney, Sydney, Australia; Personal Eyes, Sydney, Australia; Westmead Institute, Westmead, Australia; Save Sight Institute, Sydney, Australia. Electronic address: andrew.white@sydney.edu.au.
Abstract
PURPOSE: To determine the intraocular and systemic risk factor differences between a cohort of rapid glaucoma disease progressors and nonrapid disease progressors. DESIGN: Retrospective case-control study. METHODS: Setting: Five private ophthalmology clinics. STUDY POPULATION: Forty-eight rapidly progressing eyes (progression ≥1 dB mean deviation [MD]/year) and 486 non-rapidly progressing eyes (progression <1 dB MD/year). Patients were eligible if they had a diagnosis of glaucoma from their ophthalmologist and if they had greater than or equal to 5 Humphrey visual fields (24-2) conducted. Patients were excluded if their sequential visual fields showed an improvement in MD or if they had greater than 5 dB MD variation in between visits. Patients with obvious neurologic fields were excluded. OBSERVATION PROCEDURE: Clinical and demographic data (age, sex, central corneal thickness [CCT], intraocular pressure [IOP], refraction, medications), as well as medical, surgical, and ocular histories, were collected. MAIN OUTCOME MEASURES: Risk factor differences between the cohorts were measured using the independent t test, Wald χ2, and binomial regression analysis. RESULTS: Rapid progressors were older, had significantly lower CCT and baseline IOPs, and were more likely to have pseudoexfoliation, disc haemorrhages, ocular medication changes, and IOP-lowering surgery. They also had significantly higher rates of cardiovascular disease and hypotension. Subjects with cardiovascular disease were 2.33 times more likely to develop rapidly progressive glaucoma disease despite significantly lower mean and baseline IOPs. CONCLUSION: Cardiovascular disease is an important risk factor for rapid glaucoma disease progression irrespective of IOP control.
PURPOSE: To determine the intraocular and systemic risk factor differences between a cohort of rapid glaucoma disease progressors and nonrapid disease progressors. DESIGN: Retrospective case-control study. METHODS: Setting: Five private ophthalmology clinics. STUDY POPULATION: Forty-eight rapidly progressing eyes (progression ≥1 dB mean deviation [MD]/year) and 486 non-rapidly progressing eyes (progression <1 dB MD/year). Patients were eligible if they had a diagnosis of glaucoma from their ophthalmologist and if they had greater than or equal to 5 Humphrey visual fields (24-2) conducted. Patients were excluded if their sequential visual fields showed an improvement in MD or if they had greater than 5 dB MD variation in between visits. Patients with obvious neurologic fields were excluded. OBSERVATION PROCEDURE: Clinical and demographic data (age, sex, central corneal thickness [CCT], intraocular pressure [IOP], refraction, medications), as well as medical, surgical, and ocular histories, were collected. MAIN OUTCOME MEASURES: Risk factor differences between the cohorts were measured using the independent t test, Wald χ2, and binomial regression analysis. RESULTS: Rapid progressors were older, had significantly lower CCT and baseline IOPs, and were more likely to have pseudoexfoliation, disc haemorrhages, ocular medication changes, and IOP-lowering surgery. They also had significantly higher rates of cardiovascular disease and hypotension. Subjects with cardiovascular disease were 2.33 times more likely to develop rapidly progressive glaucoma disease despite significantly lower mean and baseline IOPs. CONCLUSION:Cardiovascular disease is an important risk factor for rapid glaucoma disease progression irrespective of IOP control.
Authors: Carla V Valenzuela; James C Liu; Peter M Vila; Laura Simon; Michelle Doering; Judith E C Lieu Journal: Laryngoscope Date: 2018-09-19 Impact factor: 3.325
Authors: Osamah J Saeedi; Tobias Elze; Loris D'Acunto; Ramya Swamy; Vikram Hegde; Surabhi Gupta; Amin Venjara; Joby Tsai; Jonathan S Myers; Sarah R Wellik; Carlos Gustavo De Moraes; Louis R Pasquale; Lucy Q Shen; Michael V Boland Journal: Ophthalmology Date: 2019-02-04 Impact factor: 12.079
Authors: Eduardo M Normando; Tim E Yap; John Maddison; Serge Miodragovic; Paolo Bonetti; Melanie Almonte; Nada G Mohammad; Sally Ameen; Laura Crawley; Faisal Ahmed; Philip A Bloom; Maria Francesca Cordeiro Journal: Expert Rev Mol Diagn Date: 2020-05-03 Impact factor: 5.225
Authors: Harsha L Rao; Srilakshmi Dasari; Narendra K Puttaiah; Zia S Pradhan; Sasan Moghimi; Kaweh Mansouri; Carroll A B Webers; Robert N Weinreb Journal: Am J Ophthalmol Date: 2021-07-25 Impact factor: 5.258
Authors: Ryan Caezar C David; Sasan Moghimi; Jiun L Do; Huiyuan Hou; James Proudfoot; Linda M Zangwill; Alireza Kamalipour; Takashi Nishida; Carlos Gustavo De Moraes; Christopher A Girkin; Jeffrey M Liebmann; Robert N Weinreb Journal: Am J Ophthalmol Date: 2021-06-06 Impact factor: 5.488